United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USA.
J Infect Dis. 2011 Jul 15;204(2):229-36. doi: 10.1093/infdis/jir249.
To test safety and efficacy of the Rift Valley fever MP-12 (RVF MP-12) vaccine, 9 healthy adult Rhesus macaques, weighing 5-10 kg, were inoculated intramuscularly with 6 × 10(3) plaque forming units (PFUs) of MP-12 vaccine. The monkeys developed neutralizing antibody responses with no adverse effects other than a transient, low-titer viremia in 3 monkeys. Four vaccinated animals challenged intravenously with 3 × 10(6) PFUs of virulent Rift Valley fever virus strain ZH-501 (RVFV ZH-501) at 126 days after vaccination were protected against infection. The remaining 5 vaccinated monkeys along with 2 monkeys that had been vaccinated 6 years prior were completely protected against a small particle aerosol challenge of 5 × 10(5) PFUs of RVFV ZH-501. The mutagen-attenuated RVF MP-12 vaccine was determined to be protective against intravenous and aerosol challenge with virulent RVFV in these macaques, which suggests further development as a vaccine for humans is warranted.
为了测试裂谷热 MP-12（RVF MP-12）疫苗的安全性和有效性，9 只健康的成年恒河猴，体重 5-10 公斤，肌肉接种 6×10(3) 噬菌斑形成单位（PFU）的 MP-12 疫苗。猴子产生了中和抗体反应，除了 3 只猴子出现短暂的低滴度病毒血症外，没有其他不良反应。在接种后 126 天，4 只接种过疫苗的动物静脉内接受 3×10(6)PFU 的强毒裂谷热病毒株 ZH-501（RVFV ZH-501）的攻击，免受感染。其余 5 只接种过疫苗的猴子和 2 只 6 年前接种过疫苗的猴子完全免受 5×10(5)PFU 的 RVFV ZH-501 小颗粒气溶胶的挑战。这种诱变减毒的裂谷热 MP-12 疫苗被证明能预防这些猴子的静脉内和气溶胶接种强毒 RVFV，这表明进一步开发人类疫苗是合理的。
